SF3B1 and glioblastoma: Moreover, we demonstrate that SF3B1 is also an effective target in GBM in vivo since pladienolide B treatment effectively blocks GBM progression of already established GBM tumors and the GBM onset/formation in preclinical GBM mouse models.